8.3 Kidd System

8.3 Kidd System

Quick Answer: Jka and Jkb are antithetical antigens on the SLC14A1 urea transporter; Jk3 is present whenever any Kidd protein is on the cell. Jk(a−b−) is rare and enriched in Polynesian ancestry; those cells resist 2 M urea lysis. Anti-Jka is infamous for delayed hemolytic transfusion reactions: the titer falls below detectability, an anamnestic response follows transfusion of a Jk(a+) unit, and dosage plus enzyme enhancement explain why the screen looked clean. Kidd antibodies are always clinically significant. Store them as evanescent antibody history and honor historical anti-Jka even when today’s screen is negative.

Kidd is II.B.8 on the June 9, 2026 outline because it is the system that makes a technically correct current screen still the wrong crossmatch. If you remember only one honor-the-history rule on BB, this is it.

Jka, Jkb, Jk3, and the urea transporter

The Kidd glycoprotein is a urea transporter. That biochemistry is not trivia. Jk(a−b−) red cells cannot transport urea efficiently, so they resist lysis in 2 M urea — a classic screening test for the null phenotype. Ordinary Jk(a+) or Jk(b+) cells swell and lyse in urea; null cells do not. The same transporter story explains why some Jk-null people have a mild urine-concentrating defect, which the exam may mention as a clue, not as a reason to withhold transfusion.

Jka (JK1) and Jkb (JK2) are antithetical. Jk3 is the high-prevalence antigen on the Kidd protein; it is missing only on Jk(a−b−) cells. Approximate teaching frequencies:

Jk(a−b−) is not the African malaria type. That is Duffy. Do not transplant Fy(a−b−) frequencies onto Kidd. The BB geography for the Kidd null is Polynesia / Pacific Islands (a common JK02N splice mutation), with other founder populations as secondary mentions. Immunized Jk-null people can make anti-Jk3, which reacts with all Jk(a+) or Jk(b+) cells and needs other Jk(a−b−) units from a rare-donor file.

Why anti-Jka is the delayed-HTR antibody

Anti-Jka is more common than anti-Jkb. Both are IgG, always clinically significant, and capable of acute or delayed HTR and usually mild HDFN. Several properties conspire to make anti-Jka the antibody that bites after the patient has already left the hospital:

1. Evanescent titers. After the primary immunization, anti-Jka often falls below the detection limit of the antibody screen within weeks to months. The next pretransfusion sample looks clean. The antibody is not gone; it is below the method’s sensitivity.
2. Anamnestic response. Re-exposure to a Jk(a+) unit restimulates memory B cells. Antibody rises over days, coats the transfused cells, and produces a delayed hemolytic transfusion reaction: falling hemoglobin, rising bilirubin and LDH, falling haptoglobin, and a newly positive DAT, often 5–14 days after transfusion. The eluate contains anti-Jka. The post-transfusion screen, which was negative last week, is now positive.
3. Dosage. Anti-Jka may react only with Jk(a+b−) cells and look negative with Jk(a+b+) screening cells. A two-cell screen that happens to carry Jka in single dose can miss it even when a little antibody is still present. Always try to rule Kidd out on a homozygous cell.
4. Enzyme enhancement. Ficin and papain strengthen Kidd reactions. An enzyme panel is how you drag a weak anti-Jka into view. Enzymes do not destroy Kidd. DTT does not destroy Kidd. If DTT knocks the antibody out, you are in Kell territory, not Kidd territory.
5. Complement. Some Kidd antibodies bind complement. You may see in-vitro hemolysis, mixed-field appearance after partial hemolysis, or a stronger reaction in a complement-active (serum, polyspecific AHG) system than in a plasma/IgG-only card.

Put those five together and you get the classic stem: delayed HTR, previously negative screen, anti-Jka in the eluate, and a historical note that someone, somewhere, had already identified anti-Jka last year.

Honor the history, not tonight’s screen

If anti-Jka was ever identified, issue Jk(a−) red cells for life, even when the current screen and panel are negative. The same rule applies to anti-Jkb and anti-Jk3. This is not optional courtesy. It is the intervention that prevents the delayed HTR you just described. Document the antibody in the blood-bank information system, on a wallet card if the SOP uses one, and in any receiving-hospital transfer packet. An evanescent antibody that is not stored is an evanescent antibody that will be rediscovered in the DAT of a delayed HTR.

Do not wait for the titer to come back before you phenotype units. Do not accept a computer-crossmatch-only issue on a patient whose file says anti-Jka just because today’s two-cell screen is clean. Do not substitute Jk(b−) units for a historical anti-Jka. The antigen you must avoid is the one the patient already answered to.

Unit selection once the antibody is known is ordinary antigen-negative practice: type units for Jka (or Jkb), crossmatch at IAT, and issue. Jk(a−) units are findable in most inventories (about one in four European-ancestry units is Jk(a−)). Jk(a−b−) units for anti-Jk3 are not — call the rare-donor program.

HDFN from Kidd antibodies is usually milder than anti-D or anti-K. Kidd antigens are well developed on cord cells, so the antibody can cause a positive DAT and some hemolysis, but the erythroid-suppression disaster is a Kell story, not a Kidd story. Do not manage anti-Jka pregnancies with the anti-K playbook, and do not dismiss anti-Jka in a transfusion candidate because HDFN is mild.

Exam traps

• Issuing screen-compatible, Jk(a+) units to a patient with historical anti-Jka. That is the whole point of this system.
• Ruling out anti-Jka on a Jk(a+b+) cell. Demand a double-dose cell.
• Using DTT to confirm Kidd. DTT destroys Kell, not Kidd. Enzymes enhance Kidd.
• Calling Jk(a−b−) the common African phenotype. The common African null-looking type is Fy(a−b−).
• Treating a delayed HTR workup as a new warm auto just because last week’s screen was negative. Elute the DAT-positive cells; anti-Jka is waiting there.
• Withholding antigen-negative blood until you can titer the historical antibody back into view. The screen is allowed to be negative. The history is not optional.